Announced details
Sawa Yoshiki (澤芳樹) attended the council and presented his views. We plan to further deepen cooperation with the government, related organizations and partner companies.
The constituent members of the public-private council include government officials, major pharmaceutical companies in Japan and overseas, venture capital firms, startups and university representatives. Individual locations, representatives, capital, and dates of establishment are Not disclosed.
Kansai and Osaka, centered on Osaka's Nakanoshima Qross
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
Prime Minister's Office of Japan, "Public-Private Council for Enhancing Drug Discovery Capabilities"
| Item | Details |
|---|---|
| Names of Products / Services Covered | Human (allogeneic) iPS cell-derived cardiac muscle cell sheet (brand name: ReHeart®), CDMO Business, Cell Stable Supply Value Chain Consortium (VMaCS) |
| Counterparty | Government officials, Major pharmaceutical companies in Japan and overseas, Venture Capital, Startups, University representatives |
| Counterparty overview | The constituent members of the public-private council include government officials, major pharmaceutical companies in Japan and overseas, venture capital firms, startups and university representatives. Individual locations, representatives, capital, and dates of establishment are Not disclosed. |
| Relationship with the Company | Sawa Yoshiki (澤芳樹) attended the council and presented his views. We plan to further deepen cooperation with the government, related organizations and partner companies. |
| Launch date | 10 July 2026 (council meeting date; actual) |
| Applicable area | Drug Discovery, Regenerative Medicine, Biopharmaceutical development, CDMO, Large-scale cell manufacturing |
| Location | Kansai and Osaka, centered on Osaka's Nakanoshima Qross |
| Source | Prime Minister's Office of Japan, "Public-Private Council for Enhancing Drug Discovery Capabilities" |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To enhance Japan's drug discovery capabilities, build a drug discovery ecosystem connected to the world, and achieve the rapid implementation in society and full-scale industrialization of regenerative medicine and biopharmaceuticals.